Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-766 (luxdegalutamide) in Metastatic Prostate Cancer
NCT05067140Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2021
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of luxdegalutamide in prostate cancer (PCa), sponsored by Novartis. Started Sep 2021; status: active, not recruiting.
02
Drugs
luxdegalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05067140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067140.